AU2023245329A1 - Tyk2 inhibitors and uses thereof - Google Patents

Tyk2 inhibitors and uses thereof Download PDF

Info

Publication number
AU2023245329A1
AU2023245329A1 AU2023245329A AU2023245329A AU2023245329A1 AU 2023245329 A1 AU2023245329 A1 AU 2023245329A1 AU 2023245329 A AU2023245329 A AU 2023245329A AU 2023245329 A AU2023245329 A AU 2023245329A AU 2023245329 A1 AU2023245329 A1 AU 2023245329A1
Authority
AU
Australia
Prior art keywords
patient
compound
disease
tyk2
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023245329A
Other languages
English (en)
Inventor
Philip Nunn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alumis Inc
Original Assignee
Alumis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alumis Inc filed Critical Alumis Inc
Publication of AU2023245329A1 publication Critical patent/AU2023245329A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2023245329A 2022-03-29 2023-03-29 Tyk2 inhibitors and uses thereof Pending AU2023245329A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202263324754P 2022-03-29 2022-03-29
US63/324,754 2022-03-29
US202263344126P 2022-05-20 2022-05-20
US63/344,126 2022-05-20
US202263408572P 2022-09-21 2022-09-21
US63/408,572 2022-09-21
US202263429720P 2022-12-02 2022-12-02
US63/429,720 2022-12-02
PCT/US2023/016677 WO2023192351A1 (en) 2022-03-29 2023-03-29 Tyk2 inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
AU2023245329A1 true AU2023245329A1 (en) 2024-10-10

Family

ID=86142785

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023245329A Pending AU2023245329A1 (en) 2022-03-29 2023-03-29 Tyk2 inhibitors and uses thereof

Country Status (11)

Country Link
US (1) US20250205211A1 (https=)
EP (1) EP4499092A1 (https=)
JP (1) JP2025510311A (https=)
KR (1) KR20240166011A (https=)
CN (1) CN119546299A (https=)
AU (1) AU2023245329A1 (https=)
CA (1) CA3246725A1 (https=)
IL (1) IL315866A (https=)
MX (1) MX2024011860A (https=)
TW (1) TW202342000A (https=)
WO (1) WO2023192351A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025064773A1 (en) * 2023-09-20 2025-03-27 Alumis Inc. Immediate-release formulations of a tyk2 inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7631193B2 (ja) 2018-10-22 2025-02-18 アルミス インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
AU2021254764A1 (en) * 2020-04-14 2022-11-03 Gossamer Bio Services, Inc. Substituted pyridines for the treatment of inflammatory diseases
WO2021237121A1 (en) * 2020-05-21 2021-11-25 Gossamer Bio Services, Inc. Substituted pyridines

Also Published As

Publication number Publication date
EP4499092A1 (en) 2025-02-05
CA3246725A1 (en) 2023-10-05
KR20240166011A (ko) 2024-11-25
CN119546299A (zh) 2025-02-28
US20250205211A1 (en) 2025-06-26
IL315866A (en) 2024-11-01
MX2024011860A (es) 2024-11-08
TW202342000A (zh) 2023-11-01
JP2025510311A (ja) 2025-04-14
WO2023192351A1 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
JP2024506656A (ja) Ｉｒａｋ４分解剤およびその使用
US20240366585A1 (en) Therapeutic Tyrosine Kinase Inhibitors for Relapsing Multiple Sclerosis (RMS)
US20060083714A1 (en) Combination of a pde iv inhibitor and a tnf-alpha antagonist
CN120417891A (zh) Irak4降解剂及其用途
US20240350489A1 (en) Lou064 for treating multiple sclerosis
TW202345799A (zh) Ｔｙｋ２抑制劑及其用途
CN110545812A (zh) 包含pde9抑制剂的药物组合物
US20250205211A1 (en) Tyk2 inhibitors and uses thereof
MX2010014223A (es) Composiciones pediatricas para el tratamiento de esclerosis multiple.
US20260027116A1 (en) Methods of Treating Chronic Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
US20230158033A1 (en) Method of Treating Pemphigus by Administering (R)-2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-D]Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2-Enenitrile
CN110804642B (zh) Gpr174免疫学功能及其用途
CN111491633A (zh) 用组合产品治疗rsv
CN115867272A (zh) 肠道选择性jak3抑制剂的给药
TWI922445B (zh) 藉由投予(R)-2-[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧呾-3-基)哌-1-基]戊-2-烯腈治療天皰瘡之方法
US20240285563A1 (en) Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of rheumatoid arthritis
US20260069545A1 (en) Modified release formulations of ibudilast
WO2025090702A1 (en) Rilzabrutinib for use in the treatment of itch associated with atopic dermatitis and/or prurigo nodularis
CN118019540A (zh) 用于治疗多发性硬化的lou064
CN121001733A (zh) 用于治疗和预防干燥综合征的cd40l特异性tn3衍生支架
HK40113661A (zh) Cd40l特异性tn3衍生支架及其用於治疗和预防类风湿性关节炎的方法
EA051716B1 (ru) Lou064 для лечения рассеянного склероза